Inovio advances FDA review: Inovio Pharmaceuticals stock falls 3.77 percent

Published on 10/05/2026 at 15:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA decision for INO-3107 is set for October 30, 2026. Inovio Pharmaceuticals stock costs EUR 1.02 after EUR 1.06, minus 3.77 percent.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals (US45773H4092) stock fell 3.77 percent to EUR 1.02 at Lang & Schwarz on October 5, 2026, while the company advances toward an FDA decision on INO-3107. The second-quarter 2026 earnings call put the target action date at October 30, 2026, for the investigational treatment of recurrent respiratory papillomatosis.

FDA decision carries the story

According to Yahoo Finance on August 12, 2026, Inovio said the FDA had completed its late-cycle review meeting and all scheduled pre-licensure inspections for the INO-3107 biologics license application. Management also said one inspection observation had been addressed and that the review remained on track for the October 30, 2026 PDUFA date.

Investing.com reported on September 9, 2026, that 72 percent of patients in year one achieved a 50 percent to 100 percent reduction in surgeries, rising to 86 percent in year two. The trial enrolled 32 patients, making the clinical response a central test of the company's accelerated-approval case.

Loss narrows as cash supports launch

Inovio reported a USD 6.00 million net loss, or USD 0.07 diluted loss per share, for the second quarter of 2026, compared with a USD 23.50 million net loss and USD 0.61 loss per share in the second quarter of 2025, according to Yahoo Finance. Operating expenses fell from USD 23.10 million to USD 18.60 million over the same periods, a 19.00 percent decrease.

The company ended the second quarter of 2026 with USD 36.70 million in cash and short-term investments, compared with USD 58.50 million on December 31, 2025. A July 2026 equity offering added USD 18.30 million in net proceeds, and management said the resulting runway extends into late first quarter 2027 and through a potential INO-3107 launch.

Analyst target stays above the stock

MarketBeat reported on October 2, 2026, that eight research firms had a Moderate Buy consensus and an average 12-month price target of USD 3.17. Jefferies had raised its target from USD 1.80 to USD 3.00 on August 13, 2026, while Piper Sandler had issued a USD 4.00 target on August 3, 2026.

That analyst range reflects the binary nature of the catalyst: regulatory approval could move INO-3107 toward commercialization, while the FDA review remains the immediate condition for the launch plan. The company is a biotechnology developer focused on DNA medicines, with CELLECTRA devices supporting delivery into cells.

INO stock trades lower in session

INO stock was trading at EUR 1.02 at Lang & Schwarz on October 5, 2026 at 3:39 p.m. CEST, down 3.77 percent versus the prior close of EUR 1.06 on October 2, 2026. The Nasdaq-listed stock had a USD 0.56 to USD 2.72 52-week range and a USD 78.8 million market capitalization as of October 5, 2026.